RBC Capital Markets downgrades Biohaven after SK Biopharma deal

RBC Capital Markets has downgraded Biohaven, pointing to the company's recent deal with SK Biopharma as the catalyst for the call. The move puts Biohaven in focus as the market weighs what the arrangement means for the near-term setup.

The SK Biopharma transaction is what drove the action. RBC's decision to step back on the rating signals that, in the firm's view, the partnership with SK Biopharma shifts the investment picture for Biohaven in a way that warranted a lower call. That thesis will be tested. Analyst downgrades from institutions of RBC's standing tend to prompt reassessment across the broader coverage community, and whether others following Biohaven arrive at the same conclusion on the SK Biopharma deal is the next read on the name.

The definitive terms of the Biohaven and SK Biopharma arrangement have not been detailed in the downgrade, so the structure of the deal remains the variable investors need resolved. Any filing that clarifies those terms is what the tape will want to price. Watch for additional RBC commentary or responses from competing analysts on the arrangement as further detail emerges from either company.

Related reading

• Novartis shares fall more than 10% as del-desiran trial marks third setback in a week
• JPMorgan and Morgan Stanley face shareholder suits over buyout advisory roles
• Ackman and Tepper raised Meta Platforms stakes in Q2, with costs now the central question for the tape
• Lululemon (LULU) cuts full-year outlook for fourth time as Americas comparable sales drop 12%